Clinical Trial: An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)

U.S., Aug. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07105254) titled 'An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)' on July 14.

Brief Summary: An open-label single center, proof of concept study evaluating the efficacy of Roflumilast foam 0.3% in pediatric subjects with Non-Segmental Vitiligo (NSV)

Study Start Date: Aug. 01

Study Type: INTERVENTIONAL

Condition: Non-segmental Vitiligo

Intervention: DRUG: Roflumilast topical 0.3% foam

Roflumilast 0.3% topical foam

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Derm Texas, PLLC

Disclaimer: Curated by HT Syndication....